Medovate, the medical device development company, has concluded an agreement with Iowa based TLC Medical to act as an additional exclusive distributor for its FDA cleared SAFIRA™ (SAFer Injection for Regional Anaesthesia) innovation in the United States of America.
Medovate’s recent US launch of SAFIRA™ capitalises on the rapidly growing international healthcare market, and the agreement reached with TLC Medical will provide exclusivity for SAFIRA™ in Wyoming, Utah and Colorado.
Developed in collaboration with anaesthetists in the UK National Health Service (NHS), SAFIRA™ is set to help revolutionise standard clinical practice. Regional anaesthesia procedures are widely used to make a specific part of the body numb to relieve pain or allow surgical procedures to be carried out. The SAFIRA™ device incorporates a unique safety feature that helps reduce the risk of nerve damage as anaesthetic is prevented from being injected at pressures above 20psi. In addition, economic modelling has shown SAFIRA™ to have the potential to help deliver significant time and cost savings.
Amid the current COVID-19 pandemic, recent publications have recommended regional anaesthesia be considered whenever surgery is planned for a suspected or confirmed COVID-19 patient. This is because regional anaesthesia preserves respiratory function and avoids aerosolization and the potential for transmission of COVID-19 compared to general anaesthesia. The innovative new system also enables regional anaesthesia to be carried out as a one-person procedure, thus further reducing viral infection risk than the current two-person practice.
With an estimated 10 million regional anaesthesia blocks carried out each year in the US alone, SAFIRA™ has the potential to generate both significant patient safety improvements and total cost optimisation benefits.
Chris Rogers, Sales and Marketing Director, Medovate, commented:
“I am delighted to have reached agreement with TLC Medical, their experience in distributing innovative medical devices that improve patient outcomes and improve the delivery of care was a key consideration. This agreement will further support the delivery of the significant benefits we believe SAFIRA will bring to regional anesthesia in the United States. We look forward to working with Lili and her team.
Lili Sheedy, Founder TLC Medical, commented:
“At TLC Medical, we seek to bring innovative technologies that increase clinical outcomes in healthcare. We are very excited to help introduce the SAFIRA™ technology to our customers. We believe that the ability to help limit pressures during injection can help to lead to more controlled, predictable outcomes. We are thrilled to be representing SAFIRA™ technology and being part of the Medovate team in the US market.”
(Find out more about TLC Medical on the Medovate Distributors Page.)